Jazz Pharmaceuticals (JAZZ) Goodwill & Intangibles (2010 - 2026)
Jazz Pharmaceuticals' quarterly Goodwill & Intangibles came in at $6.0 billion in Q1 2026, down 7.25% year-on-year from $6.5 billion in Q1 2025, and down 3.99% quarter-over-quarter from $6.3 billion in Q4 2025.
Jazz Pharmaceuticals has reported Goodwill & Intangibles for 17 years, with the latest figure at $6.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Goodwill & Intangibles fell 7.25% year-over-year to $6.0 billion; the trailing twelve-month figure through Mar 2026 stood at $6.0 billion (down 7.25% YoY), and the FY2025 full-year result was $6.3 billion, down 3.29% from the prior year.
- Goodwill & Intangibles for Q1 2026 stood at $6.0 billion, down from $6.3 billion in the prior quarter.
- The five-year high for Goodwill & Intangibles was $8.6 billion in Q1 2022, with the low at $2.5 billion in Q4 2023.
- Average Goodwill & Intangibles over 5 years is $6.7 billion, with a median of $6.9 billion recorded in 2024.
- Year-over-year, Goodwill & Intangibles soared 287.08% in 2022 and sank 66.53% in 2023.
- Tracing JAZZ's Goodwill & Intangibles over 5 years: stood at $7.5 billion in 2022, then slumped by 66.53% to $2.5 billion in 2023, then soared by 158.3% to $6.5 billion in 2024, then decreased by 3.29% to $6.3 billion in 2025, then declined by 3.99% to $6.0 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $6.0 billion (Q1 2026), $6.3 billion (Q4 2025), and $6.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.01 Bn |
| Dec 31, 2025 | 6.26 Bn |
| Sep 30, 2025 | 6.39 Bn |
| Jun 30, 2025 | 6.61 Bn |
| Mar 31, 2025 | 6.48 Bn |
| Dec 31, 2024 | 6.47 Bn |
| Sep 30, 2024 | 6.95 Bn |
| Jun 30, 2024 | 6.82 Bn |
| Mar 31, 2024 | 6.97 Bn |
| Dec 31, 2023 | 2.51 Bn |
| Sep 30, 2023 | 7.12 Bn |
| Jun 30, 2023 | 7.45 Bn |
| Mar 31, 2023 | 7.49 Bn |
| Dec 31, 2022 | 7.49 Bn |
| Sep 30, 2022 | 7.16 Bn |
| Jun 30, 2022 | 7.93 Bn |
| Mar 31, 2022 | 8.57 Bn |
| Dec 31, 2021 | 8.98 Bn |
| Sep 30, 2021 | 1.85 Bn |
| Jun 30, 2021 | 9.48 Bn |
| Mar 31, 2021 | 3.05 Bn |
| Dec 31, 2020 | 3.15 Bn |
| Sep 30, 2020 | 3.18 Bn |
| Jun 30, 2020 | 1.02 Bn |
| Mar 31, 2020 | 3.15 Bn |
| Dec 31, 2019 | 3.36 Bn |
| Sep 30, 2019 | 3.50 Bn |
| Jun 30, 2019 | 3.61 Bn |
| Mar 31, 2019 | 3.60 Bn |
| Dec 31, 2018 | 3.66 Bn |
| Sep 30, 2018 | 3.72 Bn |
| Jun 30, 2018 | 3.78 Bn |
| Mar 31, 2018 | 3.91 Bn |
| Dec 31, 2017 | 3.93 Bn |
| Sep 30, 2017 | 3.96 Bn |
| Jun 30, 2017 | 3.96 Bn |
| Mar 31, 2017 | 3.90 Bn |
| Dec 31, 2016 | 3.91 Bn |
| Sep 30, 2016 | 4.04 Bn |
| Jun 30, 2016 | 1.96 Bn |
| Mar 31, 2016 | 2.02 Bn |
| Dec 31, 2015 | 1.84 Bn |
| Sep 30, 2015 | 1.94 Bn |
| Jun 30, 2015 | 1.95 Bn |
| Mar 31, 2015 | 1.94 Bn |
| Dec 31, 2014 | 2.14 Bn |
| Sep 30, 2014 | 2.28 Bn |
| Jun 30, 2014 | 2.44 Bn |
| Mar 31, 2014 | 2.52 Bn |
| Dec 31, 2013 | 1.26 Bn |
| Sep 30, 2013 | 1.27 Bn |
| Jun 30, 2013 | 1.26 Bn |
| Mar 31, 2013 | 1.27 Bn |
| Dec 31, 2012 | 1.31 Bn |
| Sep 30, 2012 | 1.31 Bn |
| Jun 30, 2012 | 1.44 Bn |
| Mar 31, 2012 | 565.81 Mn |
| Dec 31, 2011 | 52.80 Mn |
| Sep 30, 2011 | 54.66 Mn |
| Jun 30, 2011 | 56.52 Mn |
| Dec 31, 2010 | 60.25 Mn |